Similar articles for PMID: 24266855

Year	Number of Results
1980	1
1982	1
1983	2
1985	1
1986	1
1990	3
1991	3
1992	1
1993	1
1994	3
1995	3
1996	4
1997	4
1998	3
1999	2
2000	2
2001	9
2002	7
2003	12
2004	12
2005	17
2006	2
2007	5
2008	8
2009	11
2010	9
2011	6
2012	10
2013	9
2014	15
2015	3
2016	4
2017	4
2018	1
2019	2
2020	2
2021	1
2022	1
2024	0

1

The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.

Mühlbacher F, Neumayer HH, del Castillo D, Stefoni S, Zygmunt AJ, Budde K; European Rapamune Cyclosporine Minimization Study Group. Mühlbacher F, et al. Transpl Int. 2014 Feb;27(2):176-86. doi: 10.1111/tri.12228. Epub 2013 Nov 25. Transpl Int. 2014. PMID: 24266855 Free article. Clinical Trial.

2

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group. Schena FP, et al. Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41. Transplantation. 2009. PMID: 19155978 Clinical Trial.

3

Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.

Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM; Everolimus Pediatric Study Group. Ettenger R, et al. Pediatr Transplant. 2008 Jun;12(4):456-63. doi: 10.1111/j.1399-3046.2007.00832.x. Pediatr Transplant. 2008. PMID: 18466433 Clinical Trial.

4

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.

Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group. Gonwa TA, et al. Transplantation. 2002 Dec 15;74(11):1560-7. doi: 10.1097/00007890-200212150-00013. Transplantation. 2002. PMID: 12490789 Clinical Trial.

5

A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.

Flechner SM, Gurkan A, Hartmann A, Legendre CM, Russ GR, Campistol JM, Schena FP, Hahn CM, Li H, Korth-Bradley JM, Tai SS, Schulman SL. Flechner SM, et al. Transplantation. 2013 May 27;95(10):1233-41. doi: 10.1097/TP.0b013e318291a269. Transplantation. 2013. PMID: 23689085 Clinical Trial.

6

A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients.

Bechstein WO, Paczek L, Wramner L, Squifflet JP, Zygmunt AJ; European Rapamune Tacrolimus Study Group. Bechstein WO, et al. Transplant Proc. 2013 Jul-Aug;45(6):2133-40. doi: 10.1016/j.transproceed.2013.03.025. Transplant Proc. 2013. PMID: 23953523 Free article. Clinical Trial.

7

A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.

Baboolal K. Baboolal K. Transplantation. 2003 Apr 27;75(8):1404-8. doi: 10.1097/01.TP.0000063703.32564.3B. Transplantation. 2003. PMID: 12717239 Clinical Trial.

8

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.

Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF; Sirolimus High-Risk Study Group. Gaber AO, et al. Transplantation. 2008 Nov 15;86(9):1187-95. doi: 10.1097/TP.0b013e318187bab0. Transplantation. 2008. PMID: 19005398 Clinical Trial.

9

Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.

Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA. Santos SM, et al. Transplant Proc. 2012 Jan;44(1):154-60. doi: 10.1016/j.transproceed.2011.11.055. Transplant Proc. 2012. PMID: 22310603

10

Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.

Tedesco-Silva H, Garcia VD, Contieri FL, De Boni Monteiro de Carvalho D, Noronha IL, Gonçalves RT, de Paula FJ, Abbud-Filho M, Manfro RC, David-Neto E, Alfieri F, Ikehara E, Jiang Q, Tai SS, Medina-Pestana JO. Tedesco-Silva H, et al. Transplant Proc. 2010 Jun;42(5):1659-66. doi: 10.1016/j.transproceed.2010.02.083. Transplant Proc. 2010. PMID: 20620495 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

177 results

Results by year